AI Article Synopsis
- Breast cancer (BC) is a widespread illness and a leading cause of female mortality, prompting a study on plasma ferroportin levels in patients with BC.
- A total of 90 participants were analyzed, consisting of 60 breast cancer patients and 30 healthy controls, with blood tests measuring total serum bilirubin, AST, ALT, and ferroportin levels.
- Results indicated that breast cancer patients showed significantly higher AST and ALT levels but lower ferroportin levels compared to the control group, with no significant changes in total serum bilirubin.
Article Abstract
Breast cancer (BC) is a common malignancy and a major cause of death in women. We sought to evaluate ferroportin plasma concentration in patients with BC. A total of 90 subjects (60 BC versus 30 control healthy) enrolled in the present study. Blood sample withdrawn and serum separated for measurement of total serum bilirubin (TSB), Aspartate Transaminase (AST), alanine transaminase (ALT), ferroportin (FPN). Results: A non-significant (p<0.852) differences exists between the level TSB in BC group (0.665±0.365) compared to control group (0.654±0.191mg/dl). AST in BC group (40.1±36.0) has shown a highly significant (p>0.001) difference comparing with the control group (22.5±14.2 U/L). ALT in BC group (29.7±26.7) has shown a highly significant (p>0.004) difference comparing with the control group (18.19±9.51U/L). FPN (ng/mL) in BC group (2.47±1.59) has shown a highly significant (p>0.002) difference comparing with the control group (4.44±1.20). Conclusion: the study concluded that breast cancer was associated with elevated AST, and ALT with reduced FPN and no changes reported with TSB levels.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!